AHFS August 2025 Update

This update contains 4 new monographs and 35 revised monographs.

New monographs: Acoltremon; Avutometinib Potassium and Defactinib Hydrochloride; Clesrovimab-cfor; Telisotuzumab vedotin-tllv.

Revised monographs: Amiodarone Hydrochloride; Apomorphine Hydrochloride; Bimekizumab-bkzx; Bumetanide; BuPROPion; Canagliflozin; Cefixime; Crinecerfont; Daratumumab; Donanemab-azbt; Dronedarone Hydrochloride; Enzalutamide; Esketamine Hydrochloride; Fruquintinib; Golodirsen; Inavolisib; Laronidase; Lecanemab-irmb; Levamlodipine Maleate; Nitroglycerin (Systemic); Nivolumab; Nogapendekin Alfa Inbakicept-pmln; Olezarsen Sodium; Olipudase alfa-rpcp; PENTobarbital Sodium; QUEtiapine Fumarate; Remifentanil Hydrochloride; risperiDONE; Scopolamine; Sebelipase Alfa; Selpercatinib; Semaglutide; Tirzepatide; Vanzacaftor Calcium, Tezacaftor, and Deutivacaftor; Ziprasidone.